172 related articles for article (PubMed ID: 35409691)
1. Discriminating Potential Genetic Markers for Complete Response and Non-Complete Response Patients to Neoadjuvant Chemotherapy with Locally Advanced Rectal Cancer.
Bagaria J; Kim KO; Bagyinszky E; An SSA; Baek JH
Int J Environ Res Public Health; 2022 Mar; 19(7):. PubMed ID: 35409691
[TBL] [Abstract][Full Text] [Related]
2. [Comparison of short-term efficacy and perioperative safety between neoadjuvant therapy and total neoadjuvant therapy in patients with locally advanced rectal cancer].
Zhai ZW; Zhang KN; Wang C; Han JG; Ma HC; Wei GH; Yang Y; Wang ZJ
Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):274-280. PubMed ID: 32192307
[No Abstract] [Full Text] [Related]
3. Rectal cancer sub-clones respond differentially to neoadjuvant therapy.
Frydrych LM; Ulintz P; Bankhead A; Sifuentes C; Greenson J; Maguire L; Irwin R; Fearon ER; Hardiman KM
Neoplasia; 2019 Oct; 21(10):1051-1062. PubMed ID: 31521947
[TBL] [Abstract][Full Text] [Related]
4. Genetic variations using whole-exome sequencing might predict response for neoadjuvant chemoradiotherapy in locally advanced rectal cancer.
Lee IH; Kang K; Kang BW; Lee SJ; Bae WK; Hwang JE; Kim HJ; Park SY; Park JS; Choi GS; Kim JG
Med Oncol; 2018 Sep; 35(11):145. PubMed ID: 30206710
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of miR-21-5p as a predictive marker for complete tumor regression to neoadjuvant chemoradiotherapy in rectal cancer patients.
Lopes-Ramos CM; Habr-Gama A; Quevedo Bde S; Felício NM; Bettoni F; Koyama FC; Asprino PF; Galante PA; Gama-Rodrigues J; Camargo AA; Perez RO; Parmigiani RB
BMC Med Genomics; 2014 Dec; 7():68. PubMed ID: 25496125
[TBL] [Abstract][Full Text] [Related]
6. [Short-term outcome of programmed cell death protein1 (PD-1) antibody combined with total neoadjuvant chemoradiotherapy in the treatment of locally advanced middle-low rectal cancer with high risk factors].
Li YJ; Zhang L; Dong QS; Cai Y; Zhang YZ; Wang L; Yao YF; Zhang XY; Li ZW; Li YH; Sun YS; Wang WH; Wu AW
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Nov; 24(11):998-1007. PubMed ID: 34823301
[No Abstract] [Full Text] [Related]
7. [Rectum-preserving surgery after consolidation neoadjuvant therapy or totally neoadjuvant therapy for low rectal cancer: a preliminary report].
Huang Y; Huang SH; Chi P; Wang XJ; Lin HM; Lu XR; Ye DX; Lin Y; Deng Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):281-288. PubMed ID: 32192308
[No Abstract] [Full Text] [Related]
8. The potential predictive value of DEK expression for neoadjuvant chemoradiotherapy response in locally advanced rectal cancer.
Martinez-Useros J; Moreno I; Fernandez-Aceñero MJ; Rodriguez-Remirez M; Borrero-Palacios A; Cebrian A; Gomez Del Pulgar T; Del Puerto-Nevado L; Li W; Puime-Otin A; Perez N; Soengas MS; Garcia-Foncillas J
BMC Cancer; 2018 Feb; 18(1):144. PubMed ID: 29409457
[TBL] [Abstract][Full Text] [Related]
9. [Comparison of long-term efficacy between watch and wait strategy and total mesorectal excision in locally advanced rectal cancer patients with clinical complete response after neoadjuvant therapy].
Wang XH; Zhou CJ; Zhang S; Wang QX; Xiao WW; Ding PR; Chen G; Pan ZZ; Zeng ZF; Gao YH
Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):266-273. PubMed ID: 32192306
[No Abstract] [Full Text] [Related]
10. [Efficacy and safety of total neoadjuvant therapy versus neoadjuvant chemoradiotherapy in the treatment of locally advanced rectal cancer: a meta-analysis].
Zhang YQ; Sun KG; Lu JY; Ma J; Yao N; Qin ZH; Yao YH
Zhonghua Wei Chang Wai Ke Za Zhi; 2022 Jun; 25(6):531-538. PubMed ID: 35754218
[No Abstract] [Full Text] [Related]
11. The use of personalized biomarkers and liquid biopsies to monitor treatment response and disease recurrence in locally advanced rectal cancer after neoadjuvant chemoradiation.
Carpinetti P; Donnard E; Bettoni F; Asprino P; Koyama F; Rozanski A; Sabbaga J; Habr-Gama A; Parmigiani RB; Galante PA; Perez RO; Camargo AA
Oncotarget; 2015 Nov; 6(35):38360-71. PubMed ID: 26451609
[TBL] [Abstract][Full Text] [Related]
12. [Application of short-course radiotherapy with total neoadjuvant therapy in the treatment of middle and low rectal cancer].
Chen CJ; Yang CK; Jian JL; Guan S; Xie MM
Zhonghua Yi Xue Za Zhi; 2023 Jan; 103(4):271-277. PubMed ID: 36660788
[No Abstract] [Full Text] [Related]
13. MicroRNA expression profiles identify biomarkers for predicting the response to chemoradiotherapy in rectal cancer.
Du B; Wang X; Wu D; Wang T; Yang X; Wang J; Shi X; Chen L; Zhang W
Mol Med Rep; 2018 Aug; 18(2):1909-1916. PubMed ID: 29956755
[TBL] [Abstract][Full Text] [Related]
14. Tumor Heterogeneity as a Predictor of Response to Neoadjuvant Chemotherapy in Locally Advanced Rectal Cancer.
Greenbaum A; Martin DR; Bocklage T; Lee JH; Ness SA; Rajput A
Clin Colorectal Cancer; 2019 Jun; 18(2):102-109. PubMed ID: 30935775
[TBL] [Abstract][Full Text] [Related]
15. Somatic Mutations and Immune Alternation in Rectal Cancer Following Neoadjuvant Chemoradiotherapy.
Ji D; Yi H; Zhang D; Zhan T; Li Z; Li M; Jia J; Qiao M; Xia J; Zhai Z; Song C; Gu J
Cancer Immunol Res; 2018 Nov; 6(11):1401-1416. PubMed ID: 30282671
[TBL] [Abstract][Full Text] [Related]
16. [Genetic variations in MLH3 and MSH2 genes are associated with the sensitivity and prognosis in locally advanced rectal cancer patients receiving preoperative chemoradiotherapy].
Yang J; Wang X; Zou SM; Li HM; Xiao Q; Feng YR; Huang Y; Feng T; Chen JN; Lin DX; Li YX; Jin J; Tan W
Zhonghua Zhong Liu Za Zhi; 2018 Jun; 40(6):433-440. PubMed ID: 29936769
[No Abstract] [Full Text] [Related]
17. [Efficacy analysis of neoadjuvant chemoradiotherapy combined with total pelvic exenteration in the treatment of primary T4b rectal cancer].
Wu T; Wen L; Zhang J; Wu Y; Jiang Y; Chen G; Wang X; Huang S; Wan Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Jan; 22(1):59-65. PubMed ID: 30703795
[TBL] [Abstract][Full Text] [Related]
18. [Expression of CD133 in rectal cancer tissues and its relationship with neoadjuvant chemoradiotherapy].
Li D; Wu H; Feng R; Zhong D; Luo Y; Xiao Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2016 Jun; 19(6):690-4. PubMed ID: 27353106
[TBL] [Abstract][Full Text] [Related]
19. [Analysis on efficacy and safety of total neoadjuvant therapy in patients with locally advanced rectal cancer with high risk factors].
Ouyang GL; Meng WJ; Shu P; Deng XB; Wu B; Jiang D; Zhuang H; Shen YL; Zhou ZG; Wang ZQ; Wang X
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Apr; 22(4):349-356. PubMed ID: 31054549
[No Abstract] [Full Text] [Related]
20. [Identification of gene biomarkers to predict responses to neoadjuvant chemoradiotherapy in patients with rectal cancer and pathways enrichment analysis].
Wang XJ; Yu Q; Chi P; Lin HM; Lu XR; Huang Y; Xu ZB; Huang SH; Sun YW; Ye DX
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Dec; 22(12):1183-1187. PubMed ID: 31874536
[No Abstract] [Full Text] [Related]
[Next] [New Search]